NCT02978196View on ClinicalTrials.gov

99mTc/68Ga Labeled Anti-PD-L1 sdAb in Assessment of PD-L1 Expression in NSCLC

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

February 15, 2018

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2022

Conditions
Non-Small Cell Lung Cancer
Interventions
PROCEDURE

Injection of 99mTc-NM-01

Patient is injected with micro-dose of 99mTc-NM-01

PROCEDURE

Injection of 68Ga-NM-01

Patient is injected with micro-dose of 68Ga-NM-01

Trial Locations (1)

Unknown

Shanghai General Hospital, Shanghai

All Listed Sponsors
collaborator

NanoMab Technology (UK) Limited

INDUSTRY

lead

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

OTHER

NCT02978196 - 99mTc/68Ga Labeled Anti-PD-L1 sdAb in Assessment of PD-L1 Expression in NSCLC | Biotech Hunter | Biotech Hunter